The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...
A multi-disciplinary research team at the Wyss Institute at Harvard University, Dana-Farber Cancer Institute, and ...
Machine learning reveals unique COVID vaccine immune signatures in people living with HIV, with differences in antibodies, cytokines, and T cell responses.
Wyss Institute's DoriVac combined vaccine and adjuvant technology uses nanoscale precision enabled by DNA origami to induce broad immunity against ...
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...
ADMA Biologics ADMA reported fourth-quarter 2025 adjusted earnings per share (EPS) of 21 cents, (excluding stock-based ...
Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. Management believes these ...
ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...
Read more about Nanoparticle and AI-driven vaccines target broad protection against emerging threats on Devdiscourse ...
A futuristic “DNA origami” vaccine platform may one day outperform mRNA shots while being easier to produce and distribute. Credit: Shutterstock Scientists have developed a new DNA origami–based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results